Overview

Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

Status:
Recruiting
Trial end date:
2034-09-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from adults with relapsed/refractory B-cell malignancies (leukemia and lymphoma).
Phase:
Phase 1
Details
Lead Sponsor:
Stanford University
Treatments:
Cyclophosphamide
Fludarabine
Fludarabine phosphate